CSIMarket
 


Catalyst Pharmaceuticals Inc   (CPRX)
Other Ticker:  
 

Catalyst Pharmaceuticals Inc 's Quick Ratio

CPRX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the forth quarter 2023, Quick Ratio fell to 1.81 a new company low.

Within Major Pharmaceutical Preparations industry 58 other companies have achieved higher Quick Ratio than Catalyst Pharmaceuticals Inc in forth quarter 2023. While Quick Ratio total ranking has improved so far during the IV Quarter 2023 to 410, from total ranking in the third quarter 2023 at 566.

Explain Quick Ratio?
How much Cash & cash equivalents CPRX´s has?
What are CPRX´s Current Liabilities?


CPRX Quick Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Change 32.08 % 29.37 % 133.47 % 147.23 % 112.79 %
Y / Y Cash & cash equivalent Change -53.87 % -52.76 % -19.02 % -25.05 % 56.01 %
Quick Ratio MRQ 1.81 2.09 3.41 2.61 5.18
CPRX's Total Ranking # 410 # 566 # 907 # 1044 # 444
Seq. Current Liabilities Change 31.58 % 10.1 % -7.42 % -1.53 % 28.89 %
Seq. Cash & cash equivalent Change 13.78 % -32.34 % 20.6 % -50.32 % 16.53 %



Quick Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 59
Healthcare Sector # 122
Overall Market # 410


Quick Ratio Statistics
High Average Low
28.54 11.35 1.81
(Mar 31 2018)   (Dec 31 2023)




Financial Statements
Catalyst Pharmaceuticals Inc 's Current Liabilities $ 76 Millions Visit CPRX's Balance sheet
Catalyst Pharmaceuticals Inc 's Cash & cash equivalent $ 138 Millions Visit CPRX's Balance sheet
Source of CPRX's Sales Visit CPRX's Sales by Geography


Cumulative Catalyst Pharmaceuticals Inc 's Quick Ratio

CPRX's Quick Ratio for the trailling 12 Months

CPRX Quick Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities TTM Growth 32.08 % 29.37 % 133.47 % 147.23 % 112.79 %
Y / Y Cash & cash equivalent TTM Growth -53.87 % -52.76 % -19.02 % -25.05 % 56.01 %
Quick Ratio TTM 2.41 3.32 4.17 5.09 6.59
Total Ranking TTM # 1501 # 3548 # 713 # 2070 # 2810
Seq. Current Liabilities TTM Growth 31.58 % 10.1 % -7.42 % -1.53 % 28.89 %
Seq. Cash & cash equivalent TTM Growth 13.78 % -32.34 % 20.6 % -50.32 % 16.53 %


On the trailing twelve months basis Due to growth in Current Liabilities in the IV Quarter 2023 to $76.06 millions, cumulative Quick Ratio decreased to 2.41 below the Catalyst Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 106 other companies have achieved higher Quick Ratio than Catalyst Pharmaceuticals Inc . While Quick Ratio overall ranking has improved so far to 1501, from total ranking during the twelve months ending third quarter 2023 at 3548.

Explain Quick Ratio?
How much Cash & cash equivalents CPRX´s has?
What are CPRX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 107
Healthcare Sector # 268
Within the Market # 1501


trailing twelve months Quick Ratio Statistics
High Average Low
21.56 8.64 2.41
(Sep 30 2018)   (Dec 31 2023)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Marker Therapeutics inc   4.91 $ 15.111  Millions$ 3.075  Millions
Arvinas Inc   4.90 $ 1,261.000  Millions$ 257.100  Millions
Mineralys Therapeutics Inc   4.70 $ 49.304  Millions$ 10.482  Millions
Incannex Healthcare Inc   4.57 $ 14.554  Millions$ 3.186  Millions
Liquidia Corporation  4.51 $ 83.679  Millions$ 18.550  Millions
Siga Technologies Inc  4.50 $ 150.146  Millions$ 33.329  Millions
Legend Biotech Corporation  4.43 $ 1,277.713  Millions$ 288.531  Millions
Urogen Pharma Ltd   4.39 $ 136.968  Millions$ 31.212  Millions
Adc Therapeutics Sa  4.21 $ 278.598  Millions$ 66.203  Millions
Arcus Biosciences Inc   4.13 $ 759.000  Millions$ 184.000  Millions
Aadi Bioscience Inc   4.12 $ 108.845  Millions$ 26.395  Millions
Intra cellular Therapies Inc   4.03 $ 497.941  Millions$ 123.545  Millions
Foghorn Therapeutics Inc   4.01 $ 234.057  Millions$ 58.436  Millions
Zai Lab Limited  3.97 $ 806.451  Millions$ 203.067  Millions
Corvus Pharmaceuticals Inc   3.95 $ 27.149  Millions$ 6.869  Millions
Arcutis Biotherapeutics Inc   3.93 $ 183.463  Millions$ 46.668  Millions
Aclaris Therapeutics Inc   3.90 $ 119.106  Millions$ 30.526  Millions
United Therapeutics Corporation  3.89 $ 2,994.100  Millions$ 769.000  Millions
Regeneron Pharmaceuticals Inc   3.66 $ 10,844.800  Millions$ 2,964.500  Millions
Ardelyx Inc   3.66 $ 184.299  Millions$ 50.393  Millions
Citius Pharmaceuticals Inc   3.65 $ 20.384  Millions$ 5.579  Millions
Benitec Biopharma Inc   3.55 $ 20.399  Millions$ 5.746  Millions
Vanda Pharmaceuticals Inc   3.53 $ 135.821  Millions$ 38.460  Millions
Corcept Therapeutics Inc  3.52 $ 368.221  Millions$ 104.505  Millions
Proqr Therapeutics N v   3.48 $ 133.196  Millions$ 38.307  Millions
Schrodinger Inc   3.46 $ 463.003  Millions$ 133.673  Millions
Moleculin Biotech Inc   3.46 $ 23.550  Millions$ 6.815  Millions
Context Therapeutics Inc   3.45 $ 14.450  Millions$ 4.192  Millions
Theriva Biologics inc   3.44 $ 23.177  Millions$ 6.738  Millions
Blueprint Medicines Corporation  3.31 $ 710.641  Millions$ 214.923  Millions

Date modified: 2024-02-29T17:27:21+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com